AMOEBA (EPA:ALMIB) - AMOEBA announces the signature of an amendment to the contract for the issuance of bonds convertible into shares with an incentive program (OCAPI) and a subordination agreement

Transparency directive : regulatory news

03/12/2018 17:45

PRESS RELEASE

AMOEBA announces the signature of an amendment to the contract for the issuance
   of bonds convertible into shares with an incentive program (OCAPI) and a
                           subordination agreement

Lyon (France), December 3, 2018 - AMOEBA (FR0011051598 - AMEBA), producer of a
biological biocide capable of eliminating bacterial risk in water, plant
protection and wound care applications, announces the signature of an amendment
to the contract for the issuance of bonds convertible into shares with an
incentive program (OCAPI) and a subordination agreement between Amoéba, Nice &
Green SA and the European Investment Bank.

By press release dated 26 July 2018, Amoeba announced the signature of an
agreement to issue bonds convertible into shares with an incentive plan (the
"Agreement") for a total nominal amount of 6 million euros with Nice & Green SA
(the "Investor"), a private company under Swiss law specialized in providing
tailored financing solutions to listed companies.

In the context of this contract, the parties agreed to make the Investor's
repayment subject in full to the loan agreement concluded between Amoeba and
the European Investment Bank on 6 October 2017, for an amount of twenty million
(20,000,000) euros (see press release dated 6 October 2017).

As part of discussions with the European Investment Bank regarding the
organization of the terms of this subordination, it was agreed between Amoeba
and the Investor to amend certain features of the Agreement described in the
appendix to this press release. These amendments resulted in the signature,
today, of an amendment No. 1 to the Contract.

In addition, the terms and conditions for subordinating the Investor's
repayment to the European Investment Bank also led to the signature today of a
subordination agreement between Amoeba, the Investor and the European
Investment Bank.

We remind you that the effective implementation of the financing will be
subject to the approval of Amoeba's shareholders at an ordinary and
extraordinary general meeting to be held on January 14, 2019 (or any other date
set by the Board of Directors), initially convened for October 10, 2018 (cf.
press releases of 26 July 2018 and 21 September 2018 and notice of postponement
published in the Bulletin des Annonces Légales Obligatoires (BALO) No. 117 of
28 September 2018), with a view in particular to delegating to the Board of
Directors the power to decide on the issuance of bonds convertible into shares
with cancellation of the shareholders' preferential subscription rights in
favor of Nice & Green S.A.

We also remind you that the bonds issuance by Amoéba and their corresponding
subscription by the Investor are subject to the fulfilment of certain
conditions precedent (see press release dated 26 July 2018).

This operation should enable the company to finance its development until June
2020. It will result in the preparation of a prospectus to be submitted to the
AMF for approval.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. Created in 2010, based in Chassieu (Lyon, France) with a
subsidiary in Canada and in the United States, Amoéba is quoted on the
compartment C of Euronext Paris. The Company is a member of the BPIfrance
Excellence network and is eligible for the PEA-PME SME equity savings plan
setup. More information on www.amoeba- biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts :

Amoéba
Valérie FILIATRE
Directeur administratif et Financier
04 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Communication financière
01 56 88 11 11
ggasparetto@actifin.fr

Disclaimer

This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 27, 2018 (a copy of which is available on
www.amoeba-biocide.com). The forward-looking statements contained in this press
release are also subject to risks not yet known to AMOEBA or not currently
considered material by AMOEBA. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or achievements
of AMOEBA to be materially different from such forward-looking statements.

ANNEXE

Résumé des modifications des caractéristiques et modalités du financement
par émission réservée d'obligations convertibles en actions (OCA) issues de
l'avenant n°1

Engagement total : 6.240.000 EUR au lieu de 6.000.000 EUR

Nombre d'OCA : 312 OCA d'une valeur nominale de 20.000 EUR au lieu de 300 OCA
d'une valeur nominale de 20.000 EUR.

Prix de souscription des OCA : 96% de la valeur nominale d'une OCA au lieu de
100% de la valeur nominale d'une OCA

Identification - Calendrier d'émission des OCA : Les OCA seront numérotées
de 1 à 312 au lieu de 1 à 300 et devront être émises par Amoeba et souscrites
immédiatement par l'Investisseur en douze (12) tranches de 520.000 euros de
valeur nominale, souscrites à hauteur de 96%, soit un prix de souscription
total par tranche de 499.200 EUR, selon le calendrier suivant durant une
période d'engagement de douze (12) mois :

Date           Nombre et numéro    Valeur nominale   Prix de souscription
                des OCA émises         totale                total

16 janvier 2019    1 à 26           520.000 euros       499.200 euros
14 février 2019   27 à 52           520.000 euros       499.200 euros
15 mars 2019      53 à 78           520.000 euros       499.200 euros
15 avril 2019     79 à 104          520.000 euros       499.200 euros
20 mai 2019      105 à 130          520.000 euros       499.200 euros
18 juin 2019     131 à 156          520.000 euros       499.200 euros
17 juillet 2019  157 à 182          520.000 euros       499.200 euros
16 août 2019     183 à 208          520.000 euros       499.200 euros

Incidence théorique de l'émission des OCA sur la base du plus bas des cours
quotidiens moyens pondérés par les volumes à la clôture de l'action Amoeba
précédant le 30 novembre 2018 sur les six derniers jours, à savoir 3.457
euros

À titre indicatif, l'incidence de l'émission de 312 OCA serait la suivante :

- Incidence de l'émission sur la quote-part des capitaux propres par action
(sur la base des capitaux propres tels qu'ils ressortent des comptes au 30 juin
2018 établis conformément au référentiel de normes internationales
financières (IFRS) et du nombre d'actions composant le capital social
d'Amoéba le 30 novembre 2018, à savoir 6 012 672 actions) :

Quote-part des capitaux propres au 30 juin 2018 (en euros)

                      Base diluée*           Base non diluée

Avant émission         9 122 541                8 087 041
Après émission de
1.962.045 actions
nouvelles résultant
de la conversion
des 312 OCA            15 012 941              13 977 441

(*) en supposant l'exercice intégral des bons de souscription de parts de
créateur d'entreprise et des bons de souscription d'actions émis et
attribués par Amoéba, exerçables ou non, donnant droit à la souscription de
457.500 actions nouvelles ainsi que l'attribution définitive de 7100 actions
gratuites soumise à une condition de présence ininterrompue.

- Incidence de l'émission sur la participation d'un actionnaire détenant
actuellement 1% du capital social d'Amoéba :

Participation de l'actionnaire (en %)

                       Base diluée*            Base non diluée

Avant émission             0.93                       1

Après émission de
1.962.045 actions
nouvelles résultant
de la conversion
des 312 OCA                0.71                      0.75

(*) en supposant l'exercice intégral des bons de souscription de parts de
créateur d'entreprise et des bons de souscription d'actions émis et
attribués par Amoeba, exerçables ou non, donnant droit à la souscription de
457 500 actions nouvelles ainsi que l'attribution définitive de 7.100 actions
gratuites soumise à une condition de présence ininterrompue.

Le cours moyen pondéré retenu pour le calcul de la dilution est le plus bas
cours moyen pondéré par les volumes à la clôture de l'action Amoéba
précédant le 30 novembre 2018 sur les six derniers jours, à savoir 3.457
euros. Cette dilution ne préjuge ni du nombre d'actions final à émettre ni
de leur prix d'émission lequel sera fixé en fonction du cours de bourse,
selon les modalités décrites ci-dessus.

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - AMOEBA announces the signature of an amendment to the contract for the issuance of bonds convertible into shares with an incentive program (OCAPI) and a subordination agreement

Transparency directive : regulatory news

AMOEBA's latest news

Other stories